Immunogenic analysis of epitope-based vaccine candidate induced by photodynamic therapy in MDA-MB-231 triple-negative breast cancer cells

Serrano-Quintero, Alina; Sequeda-Juárez, Alfonso; Pérez-Hernández, C. Angélica; Sosa-Delgado, Sara M.; Méndez-Tenorio, A.; Gallegos, Eva Ramón

doi:10.1016/j.pdpdt.2022.103174

Cited by 1 publication

(2 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…About 10–15% of all breast cancers are called triple-negative breast cancers (TNBCs) as this breast cancer subtype does not have progesterone and estrogen hormone receptors (PR or ER), and HER2 overexpression too. − This type of cancer cell is generally aggressive as it grows more rapidly. It would be worth mentioning here that only few systemic treatment options are available along with chemotherapy (CT) to treat the TNBCs. − The ‘single drug and single target’ approach does not provide great success. Moreover, eradication of the resistant cancer cells is a major challenge, where multitarget therapeutics might offer better option as it concurrently inhibits several cellular pathways and thus becomes more lethal toward cancer cells.…”

Section: Introductionmentioning

confidence: 99%

“…It would be worth mentioning here that only few systemic treatment options are available along with chemotherapy (CT) to treat the TNBCs. 1 − 5 The ‘single drug and single target’ approach does not provide great success. Moreover, eradication of the resistant cancer cells is a major challenge, where multitarget therapeutics might offer better option as it concurrently inhibits several cellular pathways and thus becomes more lethal toward cancer cells.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

In Silico Study of a Small Bioactive Molecule Targeting Topoisomerase II and P53-MDM2 Complex in Triple-Negative Breast Cancer

Singh,

Verma,

Fatima

et al. 2023

ACS Omega

View full text Add to dashboard Cite

Treatment of triple-negative breast cancer (TNBC) is very challenging as only few therapeutic options are available, including chemotherapy. Thus, a constant search for new and effective approaches of therapy that could potentially fight against TNBC and mitigate side effects is "turn-on". Recently, multitarget therapy has come up with huge possibilities, and it may possibly be useful to overcome several concurrent challenges in cancer therapy. Herein, we proposed the inhibition of both Topoisomerase II enzyme and p53-MDM2 (p53 cavity in MDM2) protein complex by the same bioactive molecules for multitarget therapy. RNA-seq analysis was performed to get a network of essential proteins involved in the apoptosis pathway by considering the triplenegative breast cancer cell line (MDA-MB-231). All of the untreated duplicate sample data were retrieved from NCBI (GSC149768). Further, via in silico screening, potent bioactive molecules were screened out to target both Topo II and the p53-MDM2 complex. The results of ligandbased screening involving docking, MMGBSA, ADME/T, MD simulation, and PCA suggested that resveratrol, a plant bioactive molecule, showed more potential binding in the same cavity of target proteins compared with doxorubicin for Topo IIα (5GWK) and etoposide for the second protein target (p53-MDM2 complex; 4OQ3) as the control drug. This is also evident from the in vitro validation in case of triple-negative breast cancer cell lines (MDA-MB-231) and Western blotting analysis. Thus, it paves the scope of multitargeting against triple-negative breast cancer.

show abstract